TY - JOUR
T1 - Progression and persistence of low-grade cervical squamous intraepithelial lesions in women living with human immunodeficiency virus
AU - Zeier, Michèle Desiré
AU - Botha, Matthys Hendrik
AU - Van Der Merwe, Frederick Haynes
AU - Eshun-Wilson, Ingrid
AU - Van Schalkwyk, Marije
AU - La Grange, Marina
AU - Mason, Deidre
AU - Louw, Mercia
AU - Nachega, Jean B.
PY - 2012/7
Y1 - 2012/7
N2 - Objective: This study aimed to investigate the progression and persistence of low-grade squamous intraepithelial lesions (SILs) in human immunodeficiency virus (HIV)-infected women. Methods: Study participants for this retrospective cohort study were 1,720 women who had LSIL as their first abnormal Pap smear. A comparison of the survival of LSIL without progression to high-grade SIL as progression-free time and the survival of SIL without clearance of the lesion as persistence of SIL was done for women of HIV-positive, HIV-negative, or unknown status using the Kaplan-Meier method. Multivariable Cox proportional hazards regression model was applied to identify independent risk factors for disease progression or persistence. Results: We found progression of LSIL not different between HIV groups but that persistence occurred more in HIV-positive women (63.8% vs 35.0%, p < .001). For the HIV group, antiretroviral therapy that was started before the first LSIL was associated with decreased risk for progression compared with no antiretroviral therapy (hazard ratio = 0.66, 95% CI = 0.54-0.81, p < .001). Antiretroviral therapy also improved clearance when corrected for excision treatment and age (hazard ratio = 1.71, 95% CI = 1.29-2.27, p < .001). Excision of LSIL reduced the risk of progression. In HIV-negative women, progression was reduced from 54.7% to 0.0% (p < .001), and from 46.9% to 6.4% in HIV-positive women (p < .001). Excision also reduced persistence in HIV-negative women from 39.5% to 7.1% (p = .001), but for HIV-positive women, the effect was smaller (from 66.3% to 45.5%, p < .001). Conclusions: Antiretroviral treatment reduced the risk for progression and persistence of LSIL in HIV-infected women.
AB - Objective: This study aimed to investigate the progression and persistence of low-grade squamous intraepithelial lesions (SILs) in human immunodeficiency virus (HIV)-infected women. Methods: Study participants for this retrospective cohort study were 1,720 women who had LSIL as their first abnormal Pap smear. A comparison of the survival of LSIL without progression to high-grade SIL as progression-free time and the survival of SIL without clearance of the lesion as persistence of SIL was done for women of HIV-positive, HIV-negative, or unknown status using the Kaplan-Meier method. Multivariable Cox proportional hazards regression model was applied to identify independent risk factors for disease progression or persistence. Results: We found progression of LSIL not different between HIV groups but that persistence occurred more in HIV-positive women (63.8% vs 35.0%, p < .001). For the HIV group, antiretroviral therapy that was started before the first LSIL was associated with decreased risk for progression compared with no antiretroviral therapy (hazard ratio = 0.66, 95% CI = 0.54-0.81, p < .001). Antiretroviral therapy also improved clearance when corrected for excision treatment and age (hazard ratio = 1.71, 95% CI = 1.29-2.27, p < .001). Excision of LSIL reduced the risk of progression. In HIV-negative women, progression was reduced from 54.7% to 0.0% (p < .001), and from 46.9% to 6.4% in HIV-positive women (p < .001). Excision also reduced persistence in HIV-negative women from 39.5% to 7.1% (p = .001), but for HIV-positive women, the effect was smaller (from 66.3% to 45.5%, p < .001). Conclusions: Antiretroviral treatment reduced the risk for progression and persistence of LSIL in HIV-infected women.
KW - HIV
KW - antiretroviral treatment
KW - low-grade cervical lesions
KW - persistence
KW - progression
UR - http://www.scopus.com/inward/record.url?scp=84863567559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863567559&partnerID=8YFLogxK
U2 - 10.1097/LGT.0b013e3182403d18
DO - 10.1097/LGT.0b013e3182403d18
M3 - Article
C2 - 22460273
AN - SCOPUS:84863567559
SN - 1089-2591
VL - 16
SP - 243
EP - 250
JO - Journal of lower genital tract disease
JF - Journal of lower genital tract disease
IS - 3
ER -